clinical trial · NCT07110038
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·phase2·recruiting·n = 25
Penile Squamous Cell Carcinoma (PSCC)Avelumabenfortumab vedotin
brief summary
The DEPECA-1 trial is the first systematic Phase II trial to evaluate response and survival to a combination of antibody-drug conjugate enfortumab vedotin plus the PD-L1 inhibitor avelumab in patients with locally advanced and metastatic penile squamous cell carcinoma (PeCa) in the 1st line setting.
started
Dec 16, 2025
primary completion
May 1, 2029
completion
Nov 1, 2030
last updated
Apr 16, 2026
official title
DEPECA-1 - DEfeating PEnile Cancer 1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol